logo-loader
viewNemaura Medical Inc

Nemaura to compare its sugarBEAT continuous glucose monitor vs highly successful CGM rival sensor

It aims to position sugarBEAT as a non-invasive, daily/flexible, cost-effective alternative to expensive and invasive continuous glucose monitors

Nemaura Medical Inc - Nemaura Medical to initiate user study comparing its sugarBEAT continuous glucose monitor directly against a highly successful rival sensor
SugarBEAT is a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every 5 minutes for up to 24 hours

Nemaura Medical Inc (NASDAQ:NMRD) announced Tuesday it is planning to initiate a user study comparing its sugarBEAT continuous glucose monitor (CGM) directly against a highly successful major incumbent CGM sensor.  

The company said its goal with the study is to position sugarBEAT as a non-invasive, daily/flexible, cost-effective alternative to traditional, expensive invasive CGMs.

“Our decision to go head-to-head vs a hugely successful CGM sensor was based on positive feedback we received from recent meetings with public health insurers in key territories in Europe,” said CEO Dr Faz Chowdhury in a statement. 

“We believe that most people with diabetes do not currently use any continuous glucose monitoring system due to the high costs and the invasiveness of current products. We believe that sugarBEAT changes this paradigm and is the first non-invasive CGM to provide the [masses] an option for daily monitoring whenever they choose at an affordable price point. We believe that this level of flexibility is a better option than any alternative CGM devices with either 7-day, 10-day, or 14-day sensor wear time currently available.”

READ: Nemaura ends 3Q with $1M in cash as it commercializes sugarBEAT glucose monitor

Chowdhury added: “We believe that sugarBEAT’s flexibility empowers users with very powerful trend data at a lower cost compared to current CGM’s, which we believe will encourage broad adoption of the system.”

SugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. The genius of SugarBEAT lies in its skin-patch technology which allows for better glucose management.

Several studies are planned over the course of this year designed to demonstrate the effectiveness of sugarBEAT to increase Time-In-Range, thus reducing HbA1C with intermittent (non-consecutive days) use over a few days per week or even month.

Initial results from studies comparing the various market-leading CGM devices indicates sugarBEAT’s accuracy to be on par with the major incumbent invasive CGM sensors, using single finger-stick blood glucose meter calibration in real-life settings, the company said. 

The first phase of the commercial launch of sugarBEAT began in the UK after Nemaura received CE Mark approval in 2019. In this initial phase, devices were supplied to a limited cohort of users while the company sought to ramp up its manufacturing operations.

The UK licensee of sugarBEAT, DB Ethitronix, is currently finalizing the launch of online sales of sugarBEAT. Concurrently, Nemaura is finalizing the launch of its subscription-based service, BEATdiabetes, aimed at reversing Type 2 diabetes and preventing prediabetes from the onset of diabetes.

The company’s stock recently traded up 16% to $3.79 a share in New York. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Nemaura Medical Inc

Price: 7.67 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $159.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab Therapeutics gets first commercial sale with Medipharm

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CFO Richard Goldstein and Special Advisor Larry Latowsky joined Steve Darling from Proactive Vancouver with news the company has signed their first contract for their slow release tablets with MediPharm.  Goldstein discusses how the...

9 hours, 59 minutes ago

3 min read